<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466919</url>
  </required_header>
  <id_info>
    <org_study_id>MOHW103-TDU-B-211-113002</org_study_id>
    <nct_id>NCT02466919</nct_id>
  </id_info>
  <brief_title>Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients</brief_title>
  <official_title>Strategy on the Increment of H. Pylori Eradication Rate and Investigating the Gastric Pathology and Antimicrobial Resistance in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung-Tai Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health and Welfare, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate H. pylori eradication rate in diabetic patients by using novel
      10-day levofloxacin-based concomitant therapy compared with conventional 10-day sequential
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori eradication rate</measure>
    <time_frame>1-4 months after eradication therapy</time_frame>
    <description>C13-UBT to confirm the H. pylori eradication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute inflammatory score</measure>
    <time_frame>1-4 weeks after gastric tissue obtained by upper endoscopy</time_frame>
    <description>Gastric tissue obtained from antrum (2 pieces), body (2 pieces) and cardia (1 piece) were scoring by modified Sydney system and specific staining. Acute inflammatory score (AIS) can be assessed by the sum of these five pathologic tissues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic inflammatory score</measure>
    <time_frame>1-4 weeks after gastric tissue obtained by upper endoscopy</time_frame>
    <description>Chronic inflammatory score (CIS) can be assessed by the sum of these five pathologic tissues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H. pylori density score</measure>
    <time_frame>1-4 weeks after gastric tissue obtained by upper endoscopy</time_frame>
    <description>H. pylori density score (HPDS) can be assessed by the sum of these five pathologic tissues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal metaplasia</measure>
    <time_frame>1-4 weeks after gastric tissue obtained by upper endoscopy</time_frame>
    <description>Presence of intestinal metaplasia can be evaluated from these five pathologic tissues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spasmolytic polypeptide expressing metaplasia</measure>
    <time_frame>1-4 weeks after gastric tissue obtained by upper endoscopy</time_frame>
    <description>Presence of spasmolytic polypeptide expressing metaplasia can be evaluated from these five pathologic tissues by special TFF-2 stains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H. pylori resistance panel</measure>
    <time_frame>1-4 weeks after H. pylori culture obtained by upper endoscopy</time_frame>
    <description>E-test evaluation for antibiotic (amoxicillin, metronidazole, clarithromycin, tetracycline and levofloxacin) resistance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Levofloxacin-based concomitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day10 Metronidazole 500 mg BID day1~day10 Levofloxacin 500 mg QD day1~day10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day5 Metronidazole 500 mg BID day6~day10 Clarithromycin 500 mg BID day6~day10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>H. pylori eradication therapy</description>
    <arm_group_label>Levofloxacin-based concomitant</arm_group_label>
    <arm_group_label>Sequential</arm_group_label>
    <other_name>Pantoloc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>H. pylori eradication therapy</description>
    <arm_group_label>Levofloxacin-based concomitant</arm_group_label>
    <arm_group_label>Sequential</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>H. pylori eradication therapy</description>
    <arm_group_label>Levofloxacin-based concomitant</arm_group_label>
    <arm_group_label>Sequential</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>H. pylori eradication therapy</description>
    <arm_group_label>Levofloxacin-based concomitant</arm_group_label>
    <other_name>Cravit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>H. pylori eradication therapy</description>
    <arm_group_label>Sequential</arm_group_label>
    <other_name>Klaricid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients with Helicobacter pylori infection

        Exclusion Criteria:

          -  Pregnancy or physically poor performance status

          -  Patients with contraindication for upper endoscopy

          -  Severe coagulopathy for endoscopic biopsy

          -  Chronic kidney disease (eGFR &lt; 50) or end stage renal disease

          -  Known allergy to interventional drugs

          -  Previous eradication failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yao-Jong Yang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>September 1, 2016</last_update_submitted>
  <last_update_submitted_qc>September 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Cheng-Kung University Hospital</investigator_affiliation>
    <investigator_full_name>Chung-Tai Wu</investigator_full_name>
    <investigator_title>National Cheng-Kung University Hospital</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

